Research has demonstrated that mutations or decreased expression of Smad4 correlate with advanced disease stages, lymph node metastasis, and reduced survival rates in cancer patients, highlighting its potential as a target for therapeutic intervention and prognostic assessment in oncology [8]. Here, SMAD4 is linked to cancer.